Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Bellone

Showing results (91-100 of 106) with videos related to

Pageof 11
Sort By:
Gynecologic and Obstetric Investigation|July 18, 2003
Influence of allogeneic blood transfusion on clinical outcome during radiotherapy for cancer of the uterine cervixA D Santin, S Bellone, R S Parrish, et al.
British Journal of Cancer|March 24, 2005
Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapyA D Santin, F Zhan, S Cane', et al.
Gynecologic and Obstetric Investigation|June 16, 2001
Phenotypic and functional analysis of tumor-infiltrating lymphocytes compared with tumor-associated lymphocytes from ascitic fluid and peripheral blood lymphocytes in patients with advanced ovarian cancerA D Santin, P L Hermonat, A Ravaggi, et al.
Journal of Endocrinological Investigation|December 2, 2022
Transition in endocrinology: predictors of drop-out of a heterogeneous population on a long-term follow-upF Prodam, M Caputo, M Romanisio, et al.
British Journal of Cancer|June 23, 2004
Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profilingA D Santin, F Zhan, S Bellone, et al.
Pituitary|November 27, 2012
Measurement of height velocity is an useful marker for monitoring pituitary function in patients who had traumatic brain injuryS Bellone, S Einaudi, M Caputo, et al.
British Journal of Cancer|April 26, 2012
Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapyS Bellone, D Roque, E Cocco, et al.
Journal of Endocrinological Investigation|April 2, 2004
Standard light breakfast inhibits circulating ghrelin level to the same extent of oral glucose load in humans, despite different impact on glucose and insulin levelsC Gottero, S Bellone, A Rapa, et al.
British Journal of Cancer|September 15, 2011
Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumabP Todeschini, E Cocco, S Bellone, et al.
British Journal of Cancer|October 1, 2014
Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivoC L Schwab, S Bellone, D P English, et al.
Pageof 11

Showing results (91-100 of 106) with videos related to

Sort By:
Pageof 11
Gynecologic and Obstetric Investigation|July 18, 2003
Influence of allogeneic blood transfusion on clinical outcome during radiotherapy for cancer of the uterine cervixA D Santin, S Bellone, R S Parrish, et al.
British Journal of Cancer|March 24, 2005
Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapyA D Santin, F Zhan, S Cane', et al.
Gynecologic and Obstetric Investigation|June 16, 2001
Phenotypic and functional analysis of tumor-infiltrating lymphocytes compared with tumor-associated lymphocytes from ascitic fluid and peripheral blood lymphocytes in patients with advanced ovarian cancerA D Santin, P L Hermonat, A Ravaggi, et al.
Journal of Endocrinological Investigation|December 2, 2022
Transition in endocrinology: predictors of drop-out of a heterogeneous population on a long-term follow-upF Prodam, M Caputo, M Romanisio, et al.
British Journal of Cancer|June 23, 2004
Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profilingA D Santin, F Zhan, S Bellone, et al.
Pituitary|November 27, 2012
Measurement of height velocity is an useful marker for monitoring pituitary function in patients who had traumatic brain injuryS Bellone, S Einaudi, M Caputo, et al.
British Journal of Cancer|April 26, 2012
Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapyS Bellone, D Roque, E Cocco, et al.
Journal of Endocrinological Investigation|April 2, 2004
Standard light breakfast inhibits circulating ghrelin level to the same extent of oral glucose load in humans, despite different impact on glucose and insulin levelsC Gottero, S Bellone, A Rapa, et al.
British Journal of Cancer|September 15, 2011
Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumabP Todeschini, E Cocco, S Bellone, et al.
British Journal of Cancer|October 1, 2014
Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivoC L Schwab, S Bellone, D P English, et al.
Pageof 11